Dissertation/Thesis Abstract

Biokonjugate als spezifische Formulierungsadditive für anti-Alzheimer Wirkstoffe
by Lawatscheck, Carmen, Ph.D., Humboldt Universitaet zu Berlin (Germany), 2019, 179; 27771609
Abstract (Summary)

Considerable efforts are devoted in Alzheimer Disease (AD) research to develop disease modifying drugs. Various studies have demonstrated that abnormal aggregation of Tau protein probably interrupts communication between cells. Tau protein aggregation can be inhibited and even preformed aggregates can be redissolved by small-molecule compounds. Unfortunately, these molecules often can only be applied in limited biotests using dimethyl sulfoxide (DMSO) as co-solvent due to their poor water solubility and bioavailability. The solubilization of selected potential anti-AD drugs by tailored peptide-poly(ethylene glycol) (PEG) conjugates enabled the specific binding und subsequent release of these drugs in DMSO-free biotests. For the design of the drug conjugate carriers, large peptide libraries have been screened using Raman or fluorescence microscopy-based methods to follow drug enrichment on certain peptide library beads which exhibit high drug affinity. Identification of peptide sequences of positive hits was performed by Matrix-assisted Laser Desorption/Ionization (MALDI)-mass spectrometry (MS/MS) fragmentation. The corresponding conjugates were synthesized; loaded with the potential drugs and the resulting highly water-soluble drug transporter complexes were analyzed. Compact and defined complexes are desirable with regard to biomedical applications. Various studies on drug-peptide interactions, specifity of drug binding and influence of the different parts of the conjugates for drug capacities were performed successfully. Generated drug transporter complexes were finally tested in DMSO free bioassays. Depending on drug and peptide structures, the complexes could reach effects comparable to the drugs solubilized by DMSO. The bioavailability of poor water-soluble anti-AD compounds was largely improved. Presumably, the new developed Raman-screening procedure can be expanded to a great extent of compounds suffering from unfavorable pharmacological characteristics.

Indexing (document details)
Advisor: Börner , Hans G , Hackenberger , Christian , Mandelkow , Eckhard
Commitee:
School: Humboldt Universitaet zu Berlin (Germany)
School Location: Germany
Source: DAI-C 81/7(E), Dissertation Abstracts International
Source Type: DISSERTATION
Subjects: Pharmacology
Keywords:
Publication Number: 27771609
ISBN: 9781392452424
Copyright © 2020 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy
ProQuest